Interventions for cutaneous molluscum contagiosum

Wouden, Johannes C. van der; Sande, Renske van der; Kruithof, Emma J.; Sollie, Annet; Suijlekom-Smit, Lisette W. A. van; Koning, Sander

doi:10.1002/14651858.cd004767.pub4

Cited by 90 publications

(83 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At high concentrations, imiquimod induces apoptosis of tumor cells via the activation of Bcl-2 proteins and the caspase family [187]. Besides FDA approved indications, topical imiquimod has been used in the treatment of several infectious skin disorders (nonanagenital cutaneous warts [188], Molluscum Contagiosum [189], cutaneous leishmaniasis [190], etc. ), neoplastic (fungoid mycosis [191], vascular tumors [192], cutaneous metastases [193], etc.)…”

Section: Pyrimidine and Purine Base Derivativesmentioning

confidence: 99%

Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes

Patinote

Karroum

Moarbess

et al. 2020

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

a b s t r a c tThe discovery of the TLRs family and more precisely its functions opened a variety of gates to modulate immunological host responses. TLRs 7/8 are located in the endosomal compartment and activate a specific signaling pathway in a MyD88-dependant manner. According to their involvement into various autoimmune, inflammatory and malignant diseases, researchers have designed diverse TLRs 7/8 ligands able to boost or block the inherent signal transduction. These modulators are often small synthetic compounds and most act as agonists and to a much lesser extent as antagonists. Some of them have reached preclinical and clinical trials, and only one has been approved by the FDA and EMA, imiquimod. The key to the success of these modulators probably lies in their combination with other therapies as recently demonstrated. We gather in this review more than 360 scientific publications, reviews and patents, relating the extensive work carried out by researchers on the design of TLRs 7/8 modulators, which are classified firstly by their biological activities (agonist or antagonist) and then by their chemical structures, which total syntheses are not discussed here. This review also reports about 90 clinical cases, thereby showing the biological interest of these modulators in multiple pathologies.

show abstract

Section: Pyrimidine and Purine Base Derivativesmentioning

confidence: 99%

Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes

Patinote

Karroum

Moarbess

et al. 2020

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…43,44 Molluscum contagiosum A vast number of treatment options ranging from physical destruction to topical and systemic agents have been suggested for the management of molluscum contagiosum (MC); however, clear evidence supporting their use is generally missing (Cochrane review). 45 Though few small randomized controlled trials and observational data reported a benefit from the use of topical imiquimod in showed that imiquimod is not effective in the treatment of MC in children. After 18 weeks of treatment, these two trials showed that imiquimod was no more effective in clearing MC than was the vehicle-containing cream (24% vs. 26-28%).…”

Section: Cutaneous Infectionsmentioning

confidence: 99%

Imiquimod in dermatology: an overview

2016

View full text Add to dashboard Cite

Imiquimod is an immune response modifier commercially available as a 3.75 and 5% cream. Topical imiquimod stimulates the innate and adaptive immune responses and induces cytokine production. This allows its use for the treatment of a wide variety of benign and malignant skin conditions due to its potential antiviral, antitumor, and immunoregulatory effects. Currently, topical imiquimod is US Food and Drug Administration (FDA)-approved for the treatment of anogenital warts, actinic keratosis, and superficial basal cell carcinomas. However, it has also shown a beneficial effect in the treatment of many other skin disorders. In this review, we describe existing evidence on the mechanism of action of topical imiquimod, its FDA-approved indications, off-label uses, and side effects.

show abstract

“…A previous systematic review by van der Wouden et al 10 acknowledged the paucity of quality evidence on which to make clinical decisions in treating MC; of note, the group endorsed expectant management of the disease due to the lack of robust data that addresses the physical destruction of lesions and drug safety. In this study, we demonstrated that the use of topical cantharidin was well-tolerated in a pediatric cohort, with no serious adverse events reported.…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double‐blind, placebo‐controlled pilot trial

et al. 2018

View full text Add to dashboard Cite

Topical cantharidin is a commonly used treatment for molluscum contagiosum (MC). However, studies validating its safety and efficacy are limited. We conducted a 6-week, randomized, double-blind, placebo-controlled trial with subsequent open-label extension to assess the safety and effectiveness of cantharidin in treating pediatric MC. Ninety-four participants with MC were randomized to receive cantharidin or placebo, with or without occlusion. The primary outcome was complete lesion clearance. Secondary outcomes included post-treatment lesion count, adverse events, and side effects. No significant differences between the study arms, including baseline lesion count, were observed. The overall mean (SD) baseline lesion count was 22.2 (12.9). The number of participants achieving total clearance is as follows: 7/23 (30.4%) in the cantharidin only arm, 10/24 (41.7%) in the cantharidin with occlusion arm, 2/25 (8.0%) in the placebo with occlusion arm, and 3/22 (13.6%) in the placebo only arm. Post hoc analysis demonstrated that 17/47 (36.2%) participants in the combined cantharidin arms achieved clearance compared to 5/47 (10.6%) in the placebo arms (P = 0.0065). The mean (SD) lesion count change from baseline was -5.1 (12.2) in the placebo only arm; the mean change (SD) was -17.4 (12.8) in the cantharidin only arm (P = 0.0033) and -15.9 (11.6) in the cantharidin with occlusion arm (P = 0.0101). No serious adverse events or side effects were observed. Topical cantharidin was well-tolerated and associated with the resolution of MC.

show abstract

Interventions for cutaneous molluscum contagiosum

Cited by 90 publications

References 90 publications

Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes

Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes

Imiquimod in dermatology: an overview

Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double‐blind, placebo‐controlled pilot trial

Contact Info

Product

Resources

About